Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2025-08-07 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of drug re-registration approval notices from a provincial drug regulatory authority. It includes details about the approved drugs, their specifications, approval numbers, and validity periods. The document emphasizes the impact on the company's production qualifications and advises investors to be cautious. There is no financial data, no mention of annual or quarterly reports, no discussion of management changes, no voting results, no legal proceedings, and no merger or acquisition activity. The document is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-08-07 Chinese
防范控股股东及关联方占用资金管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management system titled '防范控股股东及关联方占用资金管理制度' (Prevention of Controlling Shareholders and Related Parties' Misappropriation of Funds Management System) issued by the company's board. It includes definitions, rules, responsibilities, and procedures related to preventing misuse of company funds by controlling shareholders and related parties. The document references the board meeting where it was approved and states it requires shareholder meeting approval. It is a governance-related document outlining internal rules and policies rather than a financial report, audit, or announcement of voting results. It does not contain financial statements or earnings data, nor is it a brief announcement or certification. Therefore, it fits best under Governance Information (CGR). The document length is 4288 characters, which is substantive and detailed, supporting classification as a governance report rather than a short announcement.
2025-08-07 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It is a detailed internal policy document outlining the company's investor relations management practices, principles, organizational structure, and responsibilities. It includes references to compliance with laws and regulations, communication with investors, and internal governance related to investor relations. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is not a report publication announcement since it is a substantive document of over 7,000 characters detailing company policy. It is not a management change announcement or a voting result. The content fits best under Governance Information (CGR) as it details internal rules and governance practices related to investor relations management.
2025-08-07 Chinese
年报信息披露重大差错责任追究制度
Governance Information Classification · 95% confidence The document is titled as a "重大差错责任追究制度" which translates to "Major Error Responsibility Accountability System" related to the annual report information disclosure. It details internal company policies and procedures for handling significant errors in annual report disclosures, including definitions, standards for error recognition, responsibility assignment, and procedural rules. It is a governance or internal control document rather than an actual annual report or audit report. It does not contain financial statements or results but rather outlines the company's internal rules and governance practices regarding annual report disclosures. The document is not a report itself but a policy document approved by the board. Therefore, it fits best under Governance Information (CGR). The document length is 4683 characters, which is substantial and contains detailed policy content, not a brief announcement or certification. Hence, it is not RPA or RNS.
2025-08-07 Chinese
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled '董事会薪酬与考核委员会工作细则' which translates to 'Board Remuneration and Assessment Committee Working Rules'. It details the structure, responsibilities, and procedures of the board's remuneration and assessment committee. It includes references to company law, governance codes, and internal rules. There is no financial data, no report of financial results, no voting results, no announcement of a report publication, and no mention of a meeting or shareholder vote results. The document is a governance-related internal rules document about board committee operations and remuneration policies. Therefore, it fits best under Governance Information (CGR). The document length is 2833 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2025-08-07 Chinese
关于收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the receipt of a drug re-registration approval notice from the Sichuan Provincial Drug Administration. It details the approval of a specific drug product and its validity period. The document is short (653 characters) and serves as a regulatory announcement about a licensing approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types defined in the classification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-31 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.